会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 5. 发明授权
    • Method for coordinating inter-cell interference in heterogeneous network and heterogeneous network
    • 用于协调异构网络和异构网络中的小区间干扰的方法
    • US09307423B2
    • 2016-04-05
    • US14131370
    • 2012-07-09
    • Satoshi NagataJing WangYu JiangXiaoming SheLan ChenHirohito Suda
    • Satoshi NagataJing WangYu JiangXiaoming SheLan ChenHirohito Suda
    • H04W24/02H04W16/14H04W72/08H04W72/04
    • H04W24/02H04W16/14H04W72/0426H04W72/082Y02D70/122Y02D70/1262
    • Provided are a method for coordinating inter-cell interference in a heterogeneous network (HetNet) and the heterogeneous network. The method includes: forming M normal base stations and low-power nodes within coverage of the respective normal base stations in the heterogeneous network into a coordinated group; combining mute/non-mute states of bandwidths of the M normal base stations to obtain a plurality of states of the coordinated group; a user of each of the normal base stations feeding at least one first CQI back to the normal base station; a user of each of the low-power nodes feeding one or more second CQIs back to the low-power node; using the first CQI and the second CQIs as a basis to make capacity estimation of the coordinated group; and setting the mute/non-mute states of the bandwidths of the M normal base stations in accordance with a state of the coordinated group corresponding to an optimal system capacity so as to perform data transmission. In the method for coordinating interference provided by the present invention, M transmission points each including one or more normal base stations and low-power nodes covered by the respective normal base stations can be formed into a coordinated group, thereby extending processing for the normal base stations up to all the transmission points in the coordinated group.
    • 提供了一种用于协调异构网络(HetNet)和异构网络中的小区间干扰的方法。 该方法包括:将异构网络中相应正常基站的覆盖范围内的M个正常基站和低功率节点形成协调组; 组合M个正常基站的静音/非静音带宽,以获得协调组的多个状态; 每个正常基站的用户将至少一个第一CQI馈送回正常基站; 每个低功率节点的用户将一个或多个第二CQI馈送回所述低功率节点; 使用第一CQI和第二CQI作为进行协调组的容量估计的基础; 以及根据与最佳系统容量相对应的协调组的状态来设置M个正常基站的带宽的静音/非静音状态,以执行数据传输。 在本发明提供的干扰协调方法中,可以将由各个正常基站覆盖的一个或多个正常基站和低功率节点组成的M个发送点形成为协调组,从而扩展正常基站的处理 到达协调组中的所有传输点的站。
    • 8. 发明授权
    • Arylthiobenzylpiperidine derivatives
    • 芳硫基苄基哌啶衍生物
    • US07329656B2
    • 2008-02-12
    • US11231601
    • 2005-09-21
    • Mohammad R. MarzabadiYu JiangChien-An ChenKai LuKim Andersen
    • Mohammad R. MarzabadiYu JiangChien-An ChenKai LuKim Andersen
    • A61K31/4545A61K31/444A61K31/5377C07D211/04C07D401/04C07D413/14
    • C07D401/04C07D211/26C07D211/62C07D401/12C07D401/14
    • This invention is directed to Arylthiobenzylpiperidine derivatives which are ligands at the MCH1 receptor. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a pharmaceutical composition made by admixing a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a method of treating a subject suffering from depression and/or anxiety which comprises administering to the subject a therapeutically effective amount of a compound of the subject invention. This invention also provides a method of treating a subject suffering from obesity which comprises administering to the subject a therapeutically effective amount of a compound of the subject invention.
    • 本发明涉及作为MCH1受体的配体的芳硫基苄基哌啶衍生物。 本发明提供了包含治疗有效量的本发明化合物和药学上可接受的载体的药物组合物。 本发明还提供通过混合治疗有效量的本发明化合物和药学上可接受的载体制备的药物组合物。 本发明还提供了制备药物组合物的方法,其包括将治疗有效量的本发明化合物和药学上可接受的载体组合。 本发明还提供了治疗患有抑郁症和/或焦虑症的受试者的方法,其包括向受试者施用治疗有效量的本发明化合物。 本发明还提供了治疗患有肥胖症的受试者的方法,其包括向受试者施用治疗有效量的本发明化合物。
    • 10. 发明申请
    • Spirocvclic piperidines as mch1 antagonists and uses thereof
    • 作为mch1拮抗剂的西吡唑哌啶及其用途
    • US20060173027A1
    • 2006-08-03
    • US10518939
    • 2003-07-03
    • Mohammad MarzabadiYu JiangKai LuChien-An ChenJohn De LeonJohn WetzelKim Andersen
    • Mohammad MarzabadiYu JiangKai LuChien-An ChenJohn De LeonJohn WetzelKim Andersen
    • A61K31/4747
    • C07D221/20C07D401/06C07D401/12C07D405/12C07D409/12C07D413/12C07D491/10
    • This invention is directed to compounds which are selective antagonists for melanin concentrating hormone-1 (MCH1) receptors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention provides a pharmaceutical composition made by combining a therapeutically effective amount of the compound of this invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a method of reducing the body mass of a subject which comprises administering to the subject an amount of a compound of the invention effective to reduce the body mass of the subject. This invention further provides a method of treating a subject suffering from depression and/or anxiety which comprises administering to the subject an amount of a compound of the invention effective to treat the subject=s depression and/or anxiety. This invention further provides a method of treating a subject suffering from a urinary disorder.
    • 本发明涉及作为黑色素浓缩激素-1(MCH1)受体的选择性拮抗剂的化合物。 本发明提供了包含治疗有效量的本发明化合物和药学上可接受的载体的药物组合物。 本发明提供通过将治疗有效量的本发明化合物与药学上可接受的载体组合而成的药物组合物。 本发明还提供了制备药物组合物的方法,其包括将治疗有效量的本发明化合物和药学上可接受的载体组合。 本发明还提供减少受试者体重的方法,其包括向受试者施用一定量的有效减少受试者体重的本发明化合物。 本发明进一步提供了治疗患有抑郁症和/或焦虑症的受试者的方法,其包括向受试者施用有效治疗受试者抑郁症和/或焦虑的量的本发明化合物。 本发明还提供了治疗患有尿失禁的受试者的方法。